These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 19665067)

  • 1. Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared to -7/del(7q) MDS.
    Slovak ML; O'Donnell M; Smith DD; Gaal K
    Cancer Genet Cytogenet; 2009 Sep; 193(2):78-85. PubMed ID: 19665067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unbalanced translocation der(1;7)(q10;p10) defines a unique clinicopathological subgroup of myeloid neoplasms.
    Sanada M; Uike N; Ohyashiki K; Ozawa K; Lili W; Hangaishi A; Kanda Y; Chiba S; Kurokawa M; Omine M; Mitani K; Ogawa S
    Leukemia; 2007 May; 21(5):992-7. PubMed ID: 17315020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome.
    Cordoba I; González-Porras JR; Nomdedeu B; Luño E; de Paz R; Such E; Tormo M; Vallespi T; Collado R; Xicoy B; Andreu R; Muñoz JA; Solé F; Cervera J; del Cañizo C;
    Cancer; 2012 Jan; 118(1):127-33. PubMed ID: 21717439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Derivative (1;7)(q10;p10) in multiple myeloma. A sign of therapy-related hidden myelodysplastic syndrome.
    Ishii Y; Hsiao HH; Sashida G; Ito Y; Miyazawa K; Kodama A; Ohyashiki JH; Ohyashiki K
    Cancer Genet Cytogenet; 2006 Jun; 167(2):131-7. PubMed ID: 16737912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional cytogenetic changes and previous genotoxic exposure predict unfavorable prognosis in myelodysplastic syndromes and acute myeloid leukemia with der(1;7)(q10;p10).
    Hsiao HH; Sashida G; Ito Y; Kodama A; Fukutake K; Ohyashiki JH; Ohyashiki K
    Cancer Genet Cytogenet; 2006 Mar; 165(2):161-6. PubMed ID: 16527611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The der(1;7)(q10;p10) defining a distinct profile from -7/del(7q) in myelodysplastic syndromes: A systematic review and meta-analysis.
    Lang W; Luo Y; Wang L; Zhang Y; Hu C; Wang H; Tong H
    Cancer Med; 2024 Jan; 13(1):e6890. PubMed ID: 38164059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [der(1;7) (q10;p10) in three patients with malignant hematologic disorders].
    Yokoo H; Okada Y; Tominaga K; Tsuji M; Takagi T; Maseki N; Sakurai M; Kaneko Y
    Rinsho Ketsueki; 1992 Dec; 33(12):1829-33. PubMed ID: 1479694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
    Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chromosomal structural changes in patients with myelodysplastic syndrome].
    Yu Y; Liu XP; Liu SH; Yu MH; Zhang Y; Xiao ZJ
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2693-7. PubMed ID: 18167247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
    Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
    Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unbalanced whole-arm translocation der(5;19)(p10;q10) is a novel and recurrent cytogenetic aberration in myelodysplastic syndrome.
    Yamamoto K; Okamura A; Katayama Y; Shimoyama M; Matsui T
    Leuk Res; 2009 Mar; 33(3):377-83. PubMed ID: 18829109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sole abnormalities of chromosome 7 in myeloid malignancies: spectrum, histopathologic correlates, and prognostic implications.
    Hussain FT; Nguyen EP; Raza S; Knudson R; Pardanani A; Hanson CA; Van Dyke D; Tefferi A
    Am J Hematol; 2012 Jul; 87(7):684-6. PubMed ID: 22565657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
    Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes.
    Ganster C; Müller-Thomas C; Haferlach C; Strupp C; Ogata K; Germing U; Hildebrandt B; Mallo M; Lübbert M; Müller C; Solé F; Götze KS; Vandenberghe P; Göhring G; Steinmetz T; Kröger N; Platzbecker U; Söling U; Raynaud S; Shirneshan K; Schanz J; Haase D
    Genes Chromosomes Cancer; 2019 Oct; 58(10):689-697. PubMed ID: 30994215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
    Ureshino H; Kizuka H; Kusaba K; Sano H; Nishioka A; Shindo T; Kubota Y; Ando T; Kojima K; Kimura S
    Int J Hematol; 2017 May; 105(5):692-696. PubMed ID: 27914067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study.
    Germing U; Lauseker M; Hildebrandt B; Symeonidis A; Cermak J; Fenaux P; Kelaidi C; Pfeilstöcker M; Nösslinger T; Sekeres M; Maciejewski J; Haase D; Schanz J; Seymour J; Kenealy M; Weide R; Lübbert M; Platzbecker U; Valent P; Götze K; Stauder R; Blum S; Kreuzer KA; Schlenk R; Ganser A; Hofmann WK; Aul C; Krieger O; Kündgen A; Haas R; Hasford J; Giagounidis A
    Leukemia; 2012 Jun; 26(6):1286-92. PubMed ID: 22289990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic characteristics of patients with signs and symptoms of myelodysplastic syndromes in the State of Pará, Brazil.
    Pinto GR; Overal DJ; Moraes LS; Van Den Berg AV; Lemos JA; Smith Mde A; Burbano RR
    Genet Mol Res; 2005 Mar; 4(1):18-30. PubMed ID: 15841432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.